Novo Nordisk Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVO NORDISK INC, and when can generic versions of NOVO NORDISK INC drugs launch?
NOVO NORDISK INC has four approved drugs.
There are four US patents protecting NOVO NORDISK INC drugs.
There are eighty-three patent family members on NOVO NORDISK INC drugs in twenty-nine countries and one hundred supplementary protection certificates in sixteen countries.
Summary for Novo Nordisk Inc
International Patents: | 83 |
US Patents: | 4 |
Tradenames: | 4 |
Ingredients: | 3 |
NDAs: | 4 |
Drug Master File Entries: | 3 |
Drugs and US Patents for Novo Nordisk Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-001 | Mar 26, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-001 | Nov 19, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | 8,114,833*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RX | Yes | Yes | 9,968,659*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo Nordisk Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,458,924 | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 7,235,627 | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE41956*PED | ⤷ Try a Trial |
Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-002 | Nov 25, 2009 | 7,018,992 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO NORDISK INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
International Patents for Novo Nordisk Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 43704 | ⤷ Try a Trial |
Germany | 60328927 | ⤷ Try a Trial |
South Korea | 20060100428 | ⤷ Try a Trial |
Spain | 2893755 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novo Nordisk Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1412357 | PA2008013 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716 |
1453521 | 300814 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
1453521 | C 2015 029 | Romania | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129 |
0770388 | 2009/012 | Ireland | ⤷ Try a Trial | PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.